Table 1. Summary of Patient Demographics and Cancer Characteristics From Those Treated With Vatalanib and Everolimus.
| Demographics | |
|---|---|
| Total No. Patients | 32 |
| Age, years, median (range) | 59 (38-74) |
| Sex M/F | 19/13 |
| Race, White/Other | 29/3 |
| Diagnosis | Total (%) |
| Prostate | 4 (12.5) |
| Lung | 1 (3.1) |
| Pancreas | 2 (6.2) |
| Colon | 1 (3.1) |
| Anal | 1 (3.1) |
| Renal | 23 (72.0) |
| Renal Cell Carcinoma Patient Demographics (n = 23) | |
| Histologic Type | Total (%) |
| Clear cell | 18 (78) |
| Other | 5 (22) |
| Motzer Risk Criteria | |
| Low risk | 1 (4.3) |
| Intermediate risk | 20 (87.0) |
| Poor risk | 2 (8.7) |
| Previous Therapy | |
| Cytokine treatment only | 1 (4.3) |
| VEGF inhibition only | 4 (17.4) |
| Cytokine treatment and VEGF inhibition | 6 (26.1) |
| No previous systemic therapy | 12 (52.2%) |
Abbreviation: VEGF = vascular endothelial growth factor.